Welcome to our dedicated page for CollPlant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies reported 2025 GAAP revenue of $2.4 million, up from $515,000 in 2024, mainly from a $2 million AbbVie milestone tied to its dermal filler program. GAAP gross profit was $1.5 million versus a gross loss a year earlier.
GAAP operating expenses fell to $13.0 million from $16.1 million following a cost-reduction plan that cut the workforce by about 25%. GAAP net loss narrowed to $11.5 million, or $0.94 per share, from $16.6 million, while non-GAAP net loss was $10.2 million.
Cash and cash equivalents were $5.6 million as of December 31, 2025, with $9.4 million used in operating activities. The company highlighted progress in regenerative breast implant preclinical studies, launch of its BioFlex 3D bioprinting kit, expansion of North American distribution, and new patents in the U.S., South Korea, and Japan.
CollPlant Biotechnologies files its annual Form 20-F as a regenerative and aesthetic medicine company built around plant-derived recombinant human collagen (rhCollagen) for medical aesthetics and 3D bioprinting.
The company reported a total comprehensive loss of $11.5 million in 2025 and an accumulated deficit of $124.8 million, with $5.6 million in cash and cash equivalents as of December 31, 2025. Management and the independent auditor note substantial doubt about CollPlant’s ability to continue as a going concern due to projected negative operating cash flows and limited liquidity.
CollPlant highlights its global development and commercialization agreement with AbbVie for dermal and soft tissue fillers, under which it has received milestone payments of $14 million in 2021, $10 million in 2023, and $2 million in 2025, while stressing there is no assurance of future payments. The report details extensive risk factors, including funding needs, manufacturing scale-up challenges, regulatory uncertainty for its novel plant-based collagen platform, dependence on strategic partners, and restrictions tied to historical R&D grants from the Israel Innovation Authority.
CollPlant Biotechnologies Ltd. received a Nasdaq notice on March 23, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its ordinary share closing bid price has been below $1.00 per share for the last 30 consecutive business days.
The company has been given a 180-day grace period, until September 21, 2026, to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. If it still does not meet the minimum bid price by that date, it may qualify for a second 180-day period if it meets other Nasdaq Capital Market initial listing standards and notifies Nasdaq of its intention to cure the deficiency, including potentially effecting a reverse share split. During this time, CollPlant’s ordinary shares remain listed and trading on the Nasdaq Capital Market while the company monitors its share price and evaluates options.
CollPlant Biotechnologies Ltd director and Chief Executive Officer Tal Yehiel filed an initial ownership report. The filing lists direct holdings of options to purchase Ordinary Shares, including grants exercisable at $4.0200 and $6.3900 per share with expirations between 2028 and 2032, covering 75,000, 37,800, 81,266 and 100,000 underlying shares. Yehiel also reports 31,137 Ordinary Shares and 80,000 restricted share units, of which 25,000 are vested and 55,000 are scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Certain awards are held through a trustee to qualify for Israeli Section 102 tax benefits.
CollPlant Biotechnologies Ltd director Alisa Lask reports existing equity awards, including options and restricted share units. She holds options to purchase 47,000 Ordinary Shares at an exercise price of $6.39 per share, expiring on May 2, 2032, all held directly.
The Form 3 also reports 10,000 restricted share units held directly. According to the footnotes, 3,125 of these units are vested and 6,875 will vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Of the options, 44,062 are already vested and 2,938 are scheduled to vest on May 2, 2026.
CollPlant Biotechnologies Ltd director Penn Elan has filed an initial Form 3 disclosing equity interests in the company. The filing reports options to purchase 10,000 ordinary shares at $4.02 expiring in 2028, 8,000 options at $6.39 expiring in 2030, and 24,000 options at $6.39 expiring in 2032, all held directly.
Elan also holds 7,500 restricted share units, of which 625 are already vested. The remaining 6,875 units vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on continued service. Most of the option grants are already fully vested or largely vested under the disclosed schedule.
CollPlant Biotechnologies director Avraham Havron has filed an initial statement of beneficial ownership, detailing his equity-based awards in the company. The filing reports options over 4,000 ordinary shares at an exercise price of $4.02 per share, expiring on January 14, 2028, which are fully vested and exercisable. It also reports options over 8,000 ordinary shares at $6.39 per share expiring on August 27, 2030, and options over 24,000 ordinary shares at $6.39 per share expiring on May 2, 2032, of which 22,500 are currently vested and the remaining 1,500 vest on May 2, 2026 subject to continued service. In addition, he holds 10,000 restricted share units, with 3,125 already vested and 6,875 scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on ongoing service.
CollPlant Biotechnologies Ltd executive Bagley Bowman, VP Commercial North America, filed an initial ownership report showing 25,000 restricted share units. These RSUs vest over four years: 25% on January 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.
CollPlant Biotechnologies Ltd VP Legal Abelis Bar Berta filed an initial ownership report showing equity awards tied to company performance and continued service. The filing lists options to purchase 20,000 ordinary shares at an exercise price of $7.50 expiring on March 28, 2033, with 13,750 options already vested and 6,250 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027. It also reports 13,000 restricted share units, of which 5,686 are vested and 7,314 vest in nine equal quarterly installments between June 8, 2026 and June 8, 2028, plus a separate grant of 40,000 restricted share units vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments thereafter.
CollPlant Biotechnologies Ltd VP of Product Development Jasmine Seror has filed an initial Form 3 outlining her equity-based holdings in the company. The filing lists several option grants to purchase Ordinary Shares and restricted share unit awards, all reported as directly owned.
Seror holds options over 4,000 and 1,000 Ordinary Shares with an exercise price of $4.0200 per share, and additional options over 5,000, 6,000 and 3,600 Ordinary Shares at $6.3900 per share, with expirations between 2027 and 2032. She also holds 12,000 restricted share units, of which 5,250 are vested and 6,750 vest in nine equal quarterly installments from June 8, 2026 to June 8, 2028, and a further 45,000 restricted shares vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments. One option grant is described as fully vested and exercisable.